FDA Chalks Up Pradaxa Safety Scare To “Stimulated Reporting”
This article was originally published in The Pink Sheet Daily
Executive Summary
In a New England Journal of Medicine editorial, FDA officials stress value and safety of Boehringer Ingelheim’s novel anticoagulant Pradaxa, which is struggling amid highly publicized reports of bleeding.
You may also be interested in...
Pradaxa Increases GI Bleeding But Not Heart Attack Risk, Medicare Data Show
Higher incidence of gastrointestinal bleeding among the Medicare population contrasts with findings from an earlier Mini-Sentinel study of dabigatran and bleeding, but FDA said the disparity in results may reflect the age differences in the populations examined.
Mini-Sentinel Expanding Drug Safety Efforts To Prospective Surveillance
The effort will complement the FDA-funded project’s existing ability to retrospectively measure exposure to products and then analyze specific adverse outcomes.
Mini Sentinel Alleviates FDA Concern Over Pradaxa Bleeding Issue
Data from the pilot program a “driving factor” in the agency’s decision against changing its recommendations for the blood thinner following reports of increased serious bleeding events.